Pfizer's GC will no longer oversee the company's compliance program, under the terms of a $2.3 billion settlement agreement resolving allegations that Pfizer's executives and sales staff illegally marketed Bextra and several other drugs. Instead, the chief compliance officer at the world's largest drug maker will report directly to the CEO. The move is required by Pfizer's corporate integrity agreement, an administrative alternative to excluding Pfizer from participating in federal health care programs.
Going With Plan B: Pfizer GC No Longer Oversees Compliance
September 10, 2009